Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CWP232291 + cytarabine in relapsed/refractory AML
NCT03055286Phase 2Terminated
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Feb 2017
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of CWP232291 in acute myeloid leukemia (AML), sponsored by JW Pharmaceutical Corporation. Started Feb 2017; status: terminated.
02
Drugs
CWP232291
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03055286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055286.